摘要目的:探讨氨磺必利治疗精神分裂症的疗效与安全性。方法:选取衢州市第三医院2020年8月至2022年3月收治的精神分裂症患者90例为研究对象，采用随机数字表法分为观察组和对照组，每组45例。对照组给予奥氮平治疗，观察组给予氨磺必利治疗，两组治疗8周。比较两组总有效率、阳性与阴性症状量表（PANSS）评分、临床大体疗效量表-疾病严重程度量表（CGI-S）评分、糖脂代谢指标、副反应量表（TESS）评分及不良反应发生情况。结果:对照组总有效率为88.89%（40/45），观察组为93.33%（42/45），两组差异无统计学意义（χ 2=0.14， P > 0.05）。治疗后，观察组PANSS评分［（52.14±3.99）分］和CGI-S评分［（3.05±0.86）分］均显著低于对照组［（56.38±4.05）分、（4.34±0.92）分］（ t=5.00、6.87，均 P < 0.001）；观察组空腹血糖［（5.25±0.33）mmol/L］、总胆固醇［（4.08±0.67）mmol/L］、三酰甘油（TG）［1.29±0.35）mmol/L］、低密度脂蛋白胆固醇［（2.60±0.31）mmol/L］水平均显著低于对照组［（6.02±0.51）mmol/L、（4.71±0.59）mmol/L、（1.61±0.26）mmol/L、（2.91±0.34）mmol/L］（ t=8.50、3.61、4.92、4.52，均 P < 0.001），高密度脂蛋白胆固醇水平［（1.57±0.36）mmol/L］显著高于对照组［（1.18±0.42）mmol/L］（ t=-4.73， P < 0.001）；观察组TESS评分［（2.39±0.58）分］显著低于对照组［（2.87±0.62）分］（ t=3.79， P < 0.05）。不良反应方面，观察组嗜睡［6.67%（3/45）］、便秘［8.89%（4/45）］、体质量增加［2.22%（1/45）］发生率均显著低于对照组［73.33%（33/45）、28.89%（13/45）、17.78%（8/45）］（χ 2=4.14、4.64、4.44，均 P < 0.05）。 结论:氨磺必利治疗精神分裂症的疗效与奥氮平相当，在改善症状和疾病严重程度上优于奥氮平，安全性更好。

abstractsObjective:To investigate the clinical efficacy and safety of amisulpride in the treatment of schizophrenia.Methods:Ninety patients with schizophrenia admitted to Quzhou Third Hospital from August 2020 to March 2022 were included in this study. They were randomly divided into an observation group and a control group ( n = 45/group). The control group was treated with olanzapine, and the observation group was treated with amisulpride. All patients were treated for 8 consecutive weeks. Total response rate, Positive and Negative Syndrome Scale score, Clinical Global Impression Scale-Severity of Illness score, glucose and lipid metabolism indicators, Treatment Emergent Symptom Scale score, and adverse reactions were compared between the two groups. Results:Total response rate was 88.89% (40/45) in the control group and 93.33% (42/45) in the observation group. There was no significant difference in total response rate between the two groups ( χ2 = 0.14, P > 0.05). After treatment, the PANSS score [(52.14 ± 3.99) points] and CGI-S score [(3.05 ± 0.86) points] in the observation group were significantly lower than (56.38 ± 4.05) points and (4.34 ± 0.92) points in the control group ( t = 5.00, 6.87, both P < 0.001). The levels of fasting plasma glucose [(5.25 ± 0.33) mmol/L], total cholesterol [(4.08 ± 0.67) mmol/L], triglyceride [(1.29 ± 0.35) mmol/L], and low density lipoprotein-cholesterol [(2.60 ± 0.31) mmol/L] in the observation group were significantly lower compared with the control group [(6.02 ± 0.51) mmol/L, (4.71 ± 0.59) mmol/L, (1.61 ± 0.26) mmol/L, (2.91 ± 0.34) mmol/L, t = 8.50, 3.61, 4.92, 4.52, all P < 0.001]. High density lipoprotein-cholesterol level in the observation group was significantly higher than that in the control group [(1.57 ± 0.36) mmol/L vs. (1.18 ± 0.42) mmol/L t = -4.73, P < 0.001]. Treatment Emergent Symptom Scale score in the observation group was significantly lower than that in the control group [(2.39 ± 0.58) points vs. (2.87 ± 0.62) points, t = 3.79, P < 0.05]. The incidences of drowsiness [6.67% (3/45)], constipation [8.89% (4/45)], and weight gain [2.22% (1/45)] in the observation group were significantly lower than those in the control group [73.33% (33/45), 28.89% (13/45), 17.78% (8/45), χ2 = 4.14, 4.64, 4.44, P < 0.05]. Conclusion:The efficacy of sulfapride in the treatment of schizophrenia is equivalent to that of olanzapine. Sulfapride is better than olanzapine in improving symptoms and reducing disease severity and has better safety.